#Sustainability #Sweden #Stockholm #Leqembi #BioArctic

BioArctic Releases Annual Report and Sustainability Overview for 2025

In a significant announcement, BioArctic AB, a prominent Swedish biopharma company listed on Nasdaq Stockholm under the ticker BIOA B, has published its Annual Report and Sustainability Report for the year 2025. This comprehensive documentation is now available on their official website, providing crucial insights not only into the company’s performance but also its commitments to sustainable practices and corporate governance.

The year 2025 marked a transformational phase for BioArctic, as they successfully introduced Leqembi® (lecanemab), a groundbreaking drug that takes a proactive approach to confronting Alzheimer’s disease, onto the global market. With over two decades of exploring treatment innovations, the company achieved record profits in 2025, propelled by a solid range of license agreements and a robust product pipeline, leaving behind a legacy of achievement and looking forward to a future defined by growth. Gunilla Osswald, the CEO of BioArctic, expressed her pride in the company's accomplishments during this pivotal year, stating, "2025 was a fantastic year for BioArctic, with our breakthrough drug against Alzheimer’s disease leading the charge for a new era of growth."

The Sustainability Report, now integrated with the Annual Report, offers a structured overview of BioArctic's sustainability initiatives. These efforts are aligned with the concepts of Sustainable Innovation and Sustainable Business, underpinned by strategies designed to enhance transparency and meet stakeholder expectations. In crafting this report, BioArctic adhered to the directives set forth by the European Corporate Sustainability Reporting Directive (CSRD) and the European Sustainability Reporting Standards (ESRS), ensuring a robust framework for accountability and growth.

Furthermore, stakeholders can download the Annual Report directly from BioArctic's website, under the Investors section. The company underscores the importance of accessibility to information, thereby enhancing the investor experience and fostering a culture of transparency and accountability in the corporate landscape.

BioArctic’s pioneering spirit is also evident in its ongoing projects beyond Alzheimer’s disease, exploring potential treatments for other neurodegenerative conditions such as Parkinson’s disease and ALS. The utilization of their proprietary BrainTransporter™ technology stands out, showcasing its innovative approaches in drug development, which focuses on improving the efficacy of therapies by transporting antibodies across the blood-brain barrier.

As a publicly traded company, BioArctic is committed to disclosing vital information as mandated by the Swedish Securities Markets Act. This commitment reflects the company's dedication to maintaining open lines of communication with investors and the public. For additional inquiries related to the report or BioArctic's initiatives, stakeholders are encouraged to reach out to Oskar Bosson, VP of Communications and Investor Relations, or Anders Martin-Löf, CFO, who are readily available to provide further insights and clarity.

In summary, BioArctic's release of the Annual Report and Sustainability Report for 2025 marks a significant milestone in showcasing the company's innovative treatments and firm commitment to sustainable business practices. The integration of these reports reflects their dedication not only to addressing pressing health challenges but also to ensuring that their operations align with environmentally and socially responsible standards. As the company looks forward, the focus remains on growth and pioneering innovations that have the potential to change lives globally.